Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O G Ottmann

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Stem Cells (Dayton, Ohio)|July 21, 2001
Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cellsT Rossmanith, B Schröder, G Bug, et al.
Biotechnology Therapeutics|January 1, 1991
Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndromeF Herrmann, R Mertelsmann, A Lindemann, et al.
Annals of Hematology|October 1, 1993
Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot studyO G Ottmann, A Ganser, M Freund, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 31, 1998
Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein bindingG Stratmann, S Harder, D Hölzer, et al.
Leukemia|April 17, 2009
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABLA A Mian, M Schüll, Z Zhao, et al.
British Journal of Haematology|February 1, 1992
Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)U Hess, A Ganser, H G Schnürch, et al.
Annals of Hematology|December 3, 2003
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)B Wassmann, N Gökbuget, U J Scheuring, et al.
International Journal of Hematology|May 25, 2001
Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34+ cell expansion and maturationS Koschmieder, G Bug, B Schröder, et al.
European Cytokine Network|March 8, 2000
Interleukin-18 stimulates HIV-1 replication in a T-cell lineS A Klein, C Klebba, D Kauschat, et al.
Immunitat Und Infektion|July 1, 1992
[Enhanced lymphocyte proliferation in the presence of epidermal cells of HIV-infected patients in vitro]R P Kappus, S Berger, C A Thomas, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Stem Cells (Dayton, Ohio)|July 21, 2001
Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cellsT Rossmanith, B Schröder, G Bug, et al.
Biotechnology Therapeutics|January 1, 1991
Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndromeF Herrmann, R Mertelsmann, A Lindemann, et al.
Annals of Hematology|October 1, 1993
Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot studyO G Ottmann, A Ganser, M Freund, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 31, 1998
Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein bindingG Stratmann, S Harder, D Hölzer, et al.
Leukemia|April 17, 2009
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABLA A Mian, M Schüll, Z Zhao, et al.
British Journal of Haematology|February 1, 1992
Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)U Hess, A Ganser, H G Schnürch, et al.
Annals of Hematology|December 3, 2003
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)B Wassmann, N Gökbuget, U J Scheuring, et al.
International Journal of Hematology|May 25, 2001
Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34+ cell expansion and maturationS Koschmieder, G Bug, B Schröder, et al.
European Cytokine Network|March 8, 2000
Interleukin-18 stimulates HIV-1 replication in a T-cell lineS A Klein, C Klebba, D Kauschat, et al.
Immunitat Und Infektion|July 1, 1992
[Enhanced lymphocyte proliferation in the presence of epidermal cells of HIV-infected patients in vitro]R P Kappus, S Berger, C A Thomas, et al.
Pageof 14